DPR/240223 - ARHAI - Standardisation of antimicrobial susceptibility testing

EUCAST) clinical breakpoints and epidemiological cutoffs. Therefore EU Members States must report AST data for ECDC surveillance networks using EUCAST validated methods and interpretation of test results with EUCAST breakpoints. The respective EUCAST guidance and breakpoints need to be updated conti

nously, for example to include new antibiotic substances and new evidence regarding resistance mechanisms. The quality of ECDC surveillance of AMR is dependent on EUCAST being able to update relevant information continously. EUCAST is a non